FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2769874827> ?p ?o ?g. }

• W2769874827 endingPage "794" @default.
• W2769874827 startingPage "787" @default.
• W2769874827 abstract "With symptomatic remission and functional recovery as the overarching therapeutic objectives of antidepressant therapy, composite endpoint measures that conjointly consider both aspects of treatment are needed. This analysis evaluated the combined effect of vortioxetine on depressive symptoms and functional capacity in adults with MDD. NCT01564862, a multinational, double-blind, placebo-controlled, duloxetine-referenced study, conducted between April 2012 and February 2014, in 602 adult outpatients (18–65 years) with moderate-to-severe MDD (Montgomery-Åsberg Depression Rating Scale (MADRS) ≥ 26), a major depressive episode of ≥ 3 months’ duration, and self-reported cognitive symptoms were randomized to once-daily vortioxetine (10 or 20 mg), duloxetine (60 mg), or placebo for 8 weeks. Assessments included the University of California San Diego Performance-based Skills Assessment (UPSA) and the MADRS. Two versions of UPSA were utilized; UPSA ‒Validation of Intermediate Measures and UPSA Brief form. An aligned UPSA-B (communication and finance items) was examined for sensitivity analysis. Efficacy was analyzed versus placebo according to the dual response (change from baseline in UPSA ≥ 7 and ≥ 9 and reduction in MADRS total score from baseline ≥ 50%). Significantly more vortioxetine-treated patients were classified as dual responders for change in MADRS total score and UPSA score of ≥ 7 (clinically important difference [CID]) (27.4% vs 14.5%; P = 0.004), and change above CID (≥ 9) (23.4% vs 13.9%; P = 0.025). Duloxetine did not differ significantly from placebo for these dual response criteria. Sensitivity analysis using the aligned UPSA-B confirmed these results for vortioxetine. An exploratory analysis of a new dual outcome measure in patients with MDD. Vortioxetine, but not duloxetine, demonstrated a robust combined effect on depressive symptoms and functional capacity in patients with MDD. ClinicalTrials.gov identifier: NCT01564862; European Clinical Trials Database [EudraCT] Number 2011–005298-22." @default.
• W2769874827 created "2017-12-04" @default.
• W2769874827 creator A5050375558 @default.
• W2769874827 creator A5068850044 @default.
• W2769874827 creator A5069671267 @default.
• W2769874827 date "2018-02-01" @default.
• W2769874827 modified "2023-10-02" @default.
• W2769874827 title "Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders" @default.
• W2769874827 cites W1539382539 @default.
• W2769874827 cites W1819417743 @default.
• W2769874827 cites W1964510658 @default.
• W2769874827 cites W1967366594 @default.
• W2769874827 cites W1968526037 @default.
• W2769874827 cites W1971568036 @default.
• W2769874827 cites W1976277684 @default.
• W2769874827 cites W1983176528 @default.
• W2769874827 cites W1989405274 @default.
• W2769874827 cites W2005584135 @default.
• W2769874827 cites W2011606125 @default.
• W2769874827 cites W2025491005 @default.
• W2769874827 cites W2026735895 @default.
• W2769874827 cites W2031516346 @default.
• W2769874827 cites W2036812642 @default.
• W2769874827 cites W2039056175 @default.
• W2769874827 cites W2051255630 @default.
• W2769874827 cites W2054509928 @default.
• W2769874827 cites W2055526664 @default.
• W2769874827 cites W2063225659 @default.
• W2769874827 cites W2071223818 @default.
• W2769874827 cites W2096856326 @default.
• W2769874827 cites W2107213230 @default.
• W2769874827 cites W2111662440 @default.
• W2769874827 cites W2112568402 @default.
• W2769874827 cites W2118984041 @default.
• W2769874827 cites W2122772517 @default.
• W2769874827 cites W2132233071 @default.
• W2769874827 cites W2137296158 @default.
• W2769874827 cites W2146890278 @default.
• W2769874827 cites W2150194035 @default.
• W2769874827 cites W2151080668 @default.
• W2769874827 cites W2152229741 @default.
• W2769874827 cites W2153644230 @default.
• W2769874827 cites W2156826191 @default.
• W2769874827 cites W2166700666 @default.
• W2769874827 cites W2168325076 @default.
• W2769874827 cites W2168814349 @default.
• W2769874827 cites W2170135777 @default.
• W2769874827 cites W2170883616 @default.
• W2769874827 cites W2171340584 @default.
• W2769874827 cites W2172249063 @default.
• W2769874827 cites W2332743496 @default.
• W2769874827 cites W2534049957 @default.
• W2769874827 cites W2588718263 @default.
• W2769874827 cites W4234804332 @default.
• W2769874827 doi "https://doi.org/10.1016/j.jad.2017.11.081" @default.
• W2769874827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29689693" @default.
• W2769874827 hasPublicationYear "2018" @default.
• W2769874827 type Work @default.
• W2769874827 sameAs 2769874827 @default.
• W2769874827 citedByCount "24" @default.
• W2769874827 countsByYear W27698748272018 @default.
• W2769874827 countsByYear W27698748272019 @default.
• W2769874827 countsByYear W27698748272020 @default.
• W2769874827 countsByYear W27698748272021 @default.
• W2769874827 countsByYear W27698748272022 @default.
• W2769874827 countsByYear W27698748272023 @default.
• W2769874827 crossrefType "journal-article" @default.
• W2769874827 hasAuthorship W2769874827A5050375558 @default.
• W2769874827 hasAuthorship W2769874827A5068850044 @default.
• W2769874827 hasAuthorship W2769874827A5069671267 @default.
• W2769874827 hasBestOaLocation W27698748271 @default.
• W2769874827 hasConcept C118552586 @default.
• W2769874827 hasConcept C126322002 @default.
• W2769874827 hasConcept C134362201 @default.
• W2769874827 hasConcept C138496976 @default.
• W2769874827 hasConcept C142724271 @default.
• W2769874827 hasConcept C15744967 @default.
• W2769874827 hasConcept C204787440 @default.
• W2769874827 hasConcept C27081682 @default.
• W2769874827 hasConcept C2775972397 @default.
• W2769874827 hasConcept C2777955769 @default.
• W2769874827 hasConcept C2778034309 @default.
• W2769874827 hasConcept C2779177272 @default.
• W2769874827 hasConcept C2780051608 @default.
• W2769874827 hasConcept C2780733359 @default.
• W2769874827 hasConcept C2780764818 @default.
• W2769874827 hasConcept C558461103 @default.
• W2769874827 hasConcept C70410870 @default.
• W2769874827 hasConcept C71924100 @default.
• W2769874827 hasConcept C83849319 @default.
• W2769874827 hasConceptScore W2769874827C118552586 @default.
• W2769874827 hasConceptScore W2769874827C126322002 @default.
• W2769874827 hasConceptScore W2769874827C134362201 @default.
• W2769874827 hasConceptScore W2769874827C138496976 @default.
• W2769874827 hasConceptScore W2769874827C142724271 @default.
• W2769874827 hasConceptScore W2769874827C15744967 @default.
• W2769874827 hasConceptScore W2769874827C204787440 @default.
• W2769874827 hasConceptScore W2769874827C27081682 @default.

• next